QIAGEN won FDA’s OK to introduce its PartoSure test for estimating the risk of spontaneous preterm birth to be used for women that are experiencing symptoms of preterm labor. The test identifies the presence of placental alpha microglobulin-1 (PAMG-1), a pretty good indicator that the fetal membrane has suffered a break.
The test has already been available in many countries in Europe, Asia, and other parts of the world. It is expected to be available in the U.S. sometime this year.
Info page: PartoSure test…
Via: QIAGEN…